

Centre for Health Technology Evaluation
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

5th October 2009

Dear

Multi Technology Appraisal: Bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma.

Leukaemia CARE endorses all the views and comments put forward in this statement by Myeloma UK.

If you require further information please contact me on

or at

Yours sincerely,

Leukaemia CARE
One Birch Court,
Blackpole East,
Worcestershire WR3 8SG
www.leukaemiacare.org.uk